TPI Composites files for Chapter 11 bankruptcy, plans delisting from Nasdaq
ROCHESTER HILLS, Mich. - InfuSystem Holdings, Inc. (NYSE American: INFU), a prominent health care service provider, has announced a change in leadership with the departure of Richard DiIorio as Chief Executive Officer, effective May 19, 2025. Carrie Lachance, currently the President and Chief Operating Officer, will take over the CEO role on the same date, the company disclosed today. The announcement comes as the stock has experienced significant volatility, with InvestingPro data showing a 12.5% decline in the past week and trading near its 52-week low of $5.26.
Lachance, who has been with InfuSystem for over a decade, is poised to continue the company’s growth trajectory as she steps into the CEO position. Scott Shuda, Chairman of the board, praised her extensive experience and the respect she has garnered within the company. DiIorio, who will remain as an advisor post-transition, expressed his confidence in Lachance’s capabilities to lead the company forward.
In the same announcement, InfuSystem reaffirmed its full-year 2025 financial guidance, projecting revenue growth between 8% and 10% and an Adjusted EBITDA (non-GAAP) margin surpassing 18.8%. The guidance reflects management’s expectations based on current market conditions and includes estimates of revenue and Adjusted EBITDA. According to InvestingPro data, the company maintains strong fundamentals with a 52.2% gross profit margin and a healthy current ratio of 1.82. Analysts remain optimistic about the company’s prospects, with consensus recommendations strongly favoring the stock. Get access to 6 more exclusive InvestingPro Tips and comprehensive financial analysis through the Pro Research Report.
The company’s forward-looking statements are subject to risks and uncertainties, including those detailed in their most recent annual report on Form 10-K for the year ended December 31, 2024. The financial guidance is also subject to change based on various factors, including changes in the business environment.
InfuSystem’s two-platform model caters to outpatient care for durable medical equipment manufacturers and healthcare providers. The company’s services span across Oncology, Pain Management, Wound Therapy, and Device Solutions, with a strong focus on patient care and state-of-the-art medical devices. The company has demonstrated consistent growth with a five-year revenue CAGR of 11% and maintains a moderate debt-to-equity ratio of 0.52, according to InvestingPro metrics.
This leadership change and financial outlook are based on a recent press release statement from InfuSystem Holdings, Inc.
In other recent news, InfuSystem Holdings Inc. reported its fourth-quarter earnings for 2024, which fell short of expectations. The company announced an earnings per share (EPS) of $0.04, missing the forecasted $0.085. Revenue for the quarter was $33.85 million, which did not meet the anticipated $36.05 million. Despite these misses, InfuSystem reported a 7% year-over-year increase in net revenue for the quarter and a full-year revenue rise of 7.2% to $136.4 million. The company’s operating income surged by 69% to $6.9 million, and adjusted EBITDA for the year increased by 13% to $25.3 million. Additionally, InfuSystem’s net debt decreased to $23.3 million, reflecting a strong financial position. The company also highlighted the launch of new products and expanded market presence, contributing to growth in the oncology and pain management sectors. Looking ahead, InfuSystem projects revenue growth between 8-10% for 2025, with plans to exceed an adjusted EBITDA margin of 18.8%.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.